<DOC>
	<DOCNO>NCT00081133</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , arsenic trioxide , work different way stop cancer cell divide stop grow die . Imatinib mesylate may stop growth cancer cell block enzymes necessary growth . Combining arsenic trioxide imatinib mesylate may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose arsenic trioxide give imatinib mesylate see well work treat patient accelerated phase blastic phase chronic myelogenous leukemia Philadelphia chromosome-positive acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Arsenic Trioxide Imatinib Mesylate Treating Patients With Accelerated Phase Blastic Phase Chronic Myelogenous Leukemia Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolererated dose arsenic trioxide administer imatinib mesylate patient accelerate blastic phase chronic myelogenous leukemia Philadelphia chromosome-positive acute lymphoblastic leukemia . - Determine rate complete morphologic remission bone marrow patient treat regimen . OUTLINE : This phase I dose-escalation study arsenic trioxide follow phase II study . - Phase I : - Induction therapy : Patients receive oral imatinib mesylate daily day 1-35 ( week 1-5 ) arsenic trioxide IV 1-4 hour day 1-5 , 8-12 , 15-19 , 22-26 ( week 1-4 ) . Patients undergo bone marrow evaluation week 5 . Patients achieve morphologic remission proceed consolidation therapy . Patients achieve morphologic remission receive second course imatinib mesylate week 6-10 arsenic trioxide week 6-9 . Patients re-evaluated week 10 . Patients achieve morphologic remission proceed consolidation therapy . Patients achieve morphologic remission remove study . - Consolidation therapy : Patients receive oral imatinib mesylate induction therapy approximately week 6-11 ( week 11-16* ) arsenic trioxide IV 1-4 hour day 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 ( approximately week 6-9 OR week 11-14* ) . Patients remain morphologic remission receive second course imatinib mesylate induction therapy approximately week 12-17 ( week 17-22* ) arsenic trioxide ( consolidation therapy ) approximately week 12-15 ( week 17-20* ) . NOTE : *For patient receive second course induction therapy Cohorts 6 patient receive escalate dos arsenic trioxide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive arsenic trioxide MTD imatinib mesylate phase I . Treatment phase continue absence unacceptable toxicity disease progression . After completion consolidation therapy , patient may continue imatinib mesylate study discretion physician . Patients become candidate stem cell transplantation time study remove study . PROJECTED ACCRUAL : A total 6-43 patient ( 6-12 phase I 37 [ include 6 patient phase I ] phase II ) accrue study within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one following : Chronic myelogenous leukemia ( CML ) one follow phase : Blastic phase* Accelerated phase* No appropriate donor stem cell transplantation NOTE : *Must receive highdose ( 600800 mg/day ) imatinib mesylate 3 month duration Acute lymphoblastic leukemia Philadelphia chromosome positive cytogenetic confirmation Patients bcrablpositive disease polymerase chain reaction eligible &gt; 10 % blast bone marrow No isolate extramedullary disease PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin ≤ 2 time upper limit normal ( ULN ) AST ≤ 2 time ULN INR PTT ≤ 1.5 time ULN ( except patient anticoagulation therapy ) Renal Creatinine ≤ 2 time ULN Cardiovascular Baseline QTc interval &lt; 480 m No chronic arrhythmias No active coronary artery disease Other No chronic electrolyte abnormalities No prior noncompliance medical regimen No patient consider potentially unreliable No active serious infection No active malignancy except superficial epithelial cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception least 3 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy No prior peripheral blood stem cell bone marrow transplantation Chemotherapy Prior hydroxyurea allow No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery More 4 week since prior major surgery recover Other Prior anagrelide allow No concurrent warfarin therapeutic anticoagulation Concurrent low molecular weight heparin allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
</DOC>